<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="apt15779-tbl-0004" xml:lang="en" content-type="Table" orientation="portrait" position="float">
 <label>Table 4A</label>
 <caption>
  <p>COVID‐19 experimental treatments</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <thead valign="top">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="top" rowspan="1" colspan="1">COVID‐19 treatments</th>
    <th align="left" valign="top" rowspan="1" colspan="1">
     <bold>Trials</bold>
    </th>
    <th align="left" valign="top" rowspan="1" colspan="1">
     <bold>Interaction potential</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Remdesivir</bold>
     </p>
     <p>
      <bold>(GS‐5734)</bold>
     </p>
     <p>Adults ≥40 kg: Daily IV dose over 30 min. Day 1: 200 mg</p>
     <p>Day 2‐10: 100 mg</p>
     <p>Paed &lt;40 kg: Daily IV dose over 30 min.</p>
     <p>Day 1: 5 mg/kg</p>
     <p>Day 2‐10: 2.5 mg/kg</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>ClinicalTrials.gov Identifier:</p>
     <p>NCT04292730</p>
     <p>NCT04302766</p>
     <p>NCT04292899</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">Substrate of</underline>: CYP2C8, CYP2D6, CYP3A4, transporters OATP1B1 and Pgp 
      <list list-type="simple" id="apt15779-list-0030">
       <list-item>
        <label>‐</label>
        <p>
         <bold>
          <italic>Drugs that are strong inducers will decrease remdesivir effect</italic>
         </bold>
        </p>
       </list-item>
      </list>
     </p>
     <p>
      <underline underline-style="single">Inhibits</underline>: CYP3A4, OATP1B1/3, BSEP, MRP4 and NTCP 
      <list list-type="simple" id="apt15779-list-0040">
       <list-item>
        <label>‐</label>
        <p>
         <italic>unlikely clinically significant</italic>
        </p>
       </list-item>
      </list>
     </p>
     <p>
      <underline underline-style="single">Induces</underline>: CYP1A2 and CYP2B6 
      <list list-type="simple" id="apt15779-list-0045">
       <list-item>
        <label>‐</label>
        <p>
         <italic>unlikely clinically significant</italic>
        </p>
       </list-item>
      </list>
     </p>
     <p>
      <italic>All in vitro data</italic>
     </p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Lopinavir/ Ritonavir (Kaltera) (400 mg/100 mg)</bold>
     </p>
     <p>400mg/100mg twice daily for 14 days</p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g005.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>Crushing tablet ↓ absorption ≅ 45%
      <sup>133</sup>. Use oral liquid (42.4% alcohol and 15.3% propylene glycol)
     </p>
     <p>Use compatible feeding tubes (PVC or silicone) Avoid metronidazole and disulfiram</p>
     <p>Absorbed in jejunum: NG ok; NJ may ↓ effect</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>ClinicalTrials.gov Identifier:</p>
     <p>NCT04276688</p>
     <p>Chinese Clinical Trials Registry ID:</p>
     <p>ChiCTR2000029539</p>
     <p>EU Clinical Trials Register ID:</p>
     <p>2020‐000936‐23</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Ritonavir/lopinavir:</bold>
     </p>
     <p>Lopinovir extensively metabolised by CYP3A</p>
     <p>
      <underline underline-style="single">Inhibitor of:</underline> CYP3A4 (potent*), P‐gp, BCPR, OATP1B1 
      <list list-type="simple" id="apt15779-list-0050">
       <list-item>
        <label>‐</label>
        <p>
         <bold>
          <italic>can increase concentration of drugs metabolised or substrates of these pathways</italic>
         </bold>
        </p>
       </list-item>
      </list>
     </p>
     <p>
      <underline underline-style="single">Inducer of</underline>: CYP2C9, CYP2C19, glucuronidation
     </p>
     <p>Can prolong PR interval.</p>
     <p>Rare reports of 2
      <sup>nd</sup> and 3
      <sup>rd</sup> degree atrioventricular block in patients with underlying risk factors
     </p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Chloroquine/Hydroxychloroquine</bold>
     </p>
     <p>200 mg three times a day for 10 days</p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>ClinicalTrials.gov Identifier:</p>
     <p>NCT04261517</p>
     <p>Chinese Clinical Trials Registry ID:</p>
     <p>ChiCTR2000029609</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">Metabolised by</underline>: CYP2C8, CYP3A4, CYP2D6
     </p>
     <p>
      <underline underline-style="single">Inhibited by:</underline> CYP2D6 and P‐gp
     </p>
     <p>Can prolong QTc interval, consider ECG monitoring where appropriate</p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <bold>Interferon beta</bold>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>ClinicalTrials.gov Identifier:</p>
     <p>
      <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04276688?recrs=a&amp;cond=COVID-19&amp;draw=2&amp;rank=47" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04276688?recrs=a&amp;cond=COVID-19&amp;draw=2&amp;rank=47</ext-link>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>Interferons have been reported to reduce CYP450 drug metabolism 
      <list list-type="simple" id="apt15779-list-0055">
       <list-item>
        <label>‐</label>
        <p>care with narrow therapeutic index drugs dependent on CYP450 clearance</p>
       </list-item>
      </list>
     </p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Ribavirin</bold>
     </p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>Do not crush –known teratogen.</p>
     <p>Contact hospital pharmacy for solution compounded from capsules or (SAS) product availability</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>ClinicalTrials.gov Identifier:</p>
     <p>
      <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04276688?recrs=a&amp;cond=COVID-19&amp;draw=2&amp;rank=47" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT04276688?recrs=a&amp;cond=COVID-19&amp;draw=2&amp;rank=47</ext-link>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>Not metabolised by CYP450 unlikely to contribute to CYP interactions.</p>
     <p>Inhibits inosine monophosphate dehydrogenase:</p>
     <p>Can interfere with azathioprine metabolism possibly leading to accumulation of 6‐methylthioinosine monophosphate (6‐MTIMP), which has been associated with myelotoxicity</p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Favipiravir</bold>
     </p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>Chinese Clinical Trials Registry ID:</p>
     <p>ChiCTR2000029600</p>
     <p>favipiravir plus interferon‐α</p>
     <p>ChiCTR2000029544</p>
     <p>favipiravir plus baloxavir marboxil</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">Metabolised by</underline>: Nicotinamide adenine dinucleotide phosphate (NADPH) independent and dependent enzymes.
     </p>
     <p>
      <underline underline-style="single">Inhibits:</underline>
     </p>
     <p>CYP2C8 
      <italic>(strong)</italic>
     </p>
     <p>OAT1, OAT3 (mod)</p>
     <p>CYP1A2
      <italic>(weak)</italic>, CYP2C9
      <italic>(weak)</italic>, CYP2C19
      <italic>(weak)</italic>, CYP2CD6
      <italic>(weak)</italic>, CYP2E1
      <italic>(weak)</italic>, CYP3A4
      <italic>(weak)</italic>
     </p>
     <p>Low risk QT prolongation</p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Atazanavir</bold>
     </p>
     <p>
      <inline-graphic xlink:href="APT-9999-na-g007.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
     <p>Requires pH &lt;4. Avoid antacids 2 h before and 1 hour after.</p>
     <p>Food ↑ bioavailability</p>
     <p>Absorbed in jejunum: NG ok; NJ may ↓ effect</p>
    </td>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <underline underline-style="single">Metabolised by</underline>: CYP3A4 (extensively)
     </p>
     <p>
      <underline underline-style="single">Inhibits:</underline> CYP3A4, UGT1A1, OATP1B1 (strong), CYP2C8 (weak)
     </p>
     <p>Absorption depends on low pH; drugs increasing pH will decrease atazanavir concentration</p>
     <p>Dose related prolongation in PR interval. Care with drugs increasing QT interval or in patients with pre‐existing risk factors.</p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <p>
      <bold>Nitazoxanide (prodrug)</bold>
     </p>
     <p>
      <bold>(active metabolite: tizoxanide)</bold>
     </p>
     <p>
      <bold>May be dispersible or crushed– check brand</bold>
     </p>
     <p>Take with food ‐ increases bioavailability by 50%.</p>
    </td>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1">
     <p>Nil effects on CYP450 enzymes</p>
     <p>Tizoxanide highly protein bound (&gt;99.9%) 
      <list list-type="simple" id="apt15779-list-0060">
       <list-item>
        <label>‐</label>
        <p>will compete for binding sites; monitor drugs highly protein bound with a narrow therapeutic index (ie warfarin)</p>
       </list-item>
      </list>
     </p>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <bold>Tocilizumab (IL‐6 monoclonal antibody)</bold>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>ClinicalTrials.gov Identifier:</p>
     <p>NCT04310228</p>
     <p>NCT04306705</p>
    </td>
    <td align="left" rowspan="1" colspan="1">
     <p>Nil significant drug interactions.</p>
     <p>COVID‐19 increases IL‐6 expression. Tocilizumab reduces IL‐6 expression. IL‐6 increases CYP3A4, CYP26C19, CYP2C9, CYP1A2. When tocilizumab is used to treat COVID‐19, the effect on drugs effected by these CYP enzymes is unknown.</p>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot id="apt15779-ntgp-0020">
  <fn id="apt15779-note-0020">
   <p>
    <inline-graphic xlink:href="APT-9999-na-g006.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/> Can be crushed; 
    <inline-graphic xlink:href="APT-9999-na-g007.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/> Can open capsule; 
    <inline-graphic xlink:href="APT-9999-na-g004.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/> Do not crush; 
    <inline-graphic xlink:href="APT-9999-na-g005.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/> Liquid product available.
   </p>
  </fn>
 </table-wrap-foot>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
  <license>
   <license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
  </license>
 </permissions>
</table-wrap>
